Israeli Bioscience Firm Opens US Office in Richmond
EnzySurge, an Israeli bioscience company focused on chronic wound management, announced that they will establish their U.S. office at the Virginia BioTechnology Research Park, in Richmond. EnzySurge will join several other Israeli firms as a member of the Virginia Biosciences Commercialization Center (VBCC) at the Park.
“EnzySurge’s product, DermaStream(TM), is a comprehensive yet versatile treatment for hard-to-heal chronic wounds throughout the debridement, regeneration and closure phases, designed for hospitals, clinics and home treatment,” said Donna Edmonds, executive director of the VBCC.
Pressure, venous and diabetic wounds are an increasing problem in the United States, with more than 6 million cases reported annually. Each year, more than 2.3 million Americans are treated for diabetes-related skin ulcers and more than 100,000 amputations are performed on diabetic patients due to non-healing wounds.
“We’re dedicated to developing innovative solutions that expedite wound healing and improve patients’ quality of life,” stated Amir Shiner, CEO of EnzySurge. “The VBCC program brings us closer to getting a much needed medical tool in the hands of the clinicians who can use them.”
For more information, visit http://www.dermastream.com.
